Direct comparison
Covidence vs Rayyan vs DistillerSR
Covidence vs. Rayyan vs. DistillerSR compared: screening, dedup, PRISMA diagrams, extraction, licensing, and regulatory audit trails.
Written and maintained by CASRAI Editorial Board
Last updated
Ask CASRAI · included with Regulatory Radar
Ask about Covidence vs Rayyan vs DistillerSR
Ask CASRAI answers research-administration questions and cites the passages behind every claim — and says so when the corpus does not cover something, instead of guessing. It comes with a Regulatory Radar subscription at $29 a month, alongside the daily digest of regulatory changes and the dashboard of what changed.
150 questions a day, on this site, over the API, or inside your own tools through the CASRAI MCP server.
Everything CASRAI publishes — this page, the dictionary, the guides and the news — stays free to read, with no account and no card.
How do Covidence, Rayyan, DistillerSR compare side by side?
The table below compares Covidence, Rayyan, DistillerSR across 11 procurement-relevant dimensions, from best known for through best fit.
Side-by-side comparison
| Dimension | Covidence | Rayyan | DistillerSR |
|---|---|---|---|
| Best known for | Cochrane-aligned, full screening-to-extraction workflow | Free, AI-assisted title/abstract screening | Regulatory and HTA-grade audit trails and extraction |
| Screening model | Blind dual-review with automatic conflict flagging + third-reviewer resolution | Blind dual (or multi-) reviewer screening with ML queue re-ranking | Blind dual-review with configurable multi-level forms and disagreement-triggered rules |
| Deduplication | Automated match on import; flags likely duplicates for manual confirmation | Automated match on import plus manual merge for missed near-duplicates | Automated match on import; flags likely duplicates for manual confirmation |
| PRISMA flow diagram | Built-in, auto-generated from screening counts | Generated from screening decision counts | Included in broader audit-trail reporting suite |
| Data extraction | Built-in customizable extraction forms + RoB 2/ROBINS-I appraisal | Not included — export to a separate extraction tool | Fully custom forms with conditional/branching logic and multi-reviewer reconciliation |
| Collaboration / team size | Small-to-mid team, one review at a time per license | Multiple reviewers per review at no cost; org-wide team tools are paid | Built for many concurrent reviews with project/role-level permissions |
| Access model | Paid subscription, per review or per institution | Free core screening; paid tiers for AI features and heavier usage | Enterprise licensing, sold to organizations |
| Cochrane affiliation | Cochrane's recommended screening tool; widely used by Cochrane review groups | No formal Cochrane affiliation | No formal Cochrane affiliation |
| Regulatory / audit-trail support | Decision-level audit trail; not marketed for regulatory submissions | Decision-level audit trail; not marketed for regulatory submissions | Vendor-documented controls aligned with FDA 21 CFR Part 11 / EU Annex 11 expectations |
| Export / interoperability | CSV/RIS export; structured extraction data exportable to meta-analysis tools | CSV/RIS export of screening decisions and references | CSV/RIS export; structured extraction data exportable to meta-analysis tools |
| Best fit | Cochrane or Cochrane-style reviews; teams wanting one tool end-to-end | Students, solo researchers, unfunded or first-time reviews | Regulatory/HTA submissions, CROs, high-volume review programs |
Common questions
Common questions about Covidence vs Rayyan vs DistillerSR
Is Rayyan really free?
+
Core screening — unlimited reviews, multiple reviewers per review, blind dual screening, and ML-assisted queue ranking — is free. Paid tiers add features like PICO-based filtering and higher usage limits, but a full systematic review can be screened on the free tier.
Does Cochrane require Covidence specifically?
+
Cochrane recommends Covidence and many of its review groups use it as their standard tool, but Cochrane does not contractually require a specific screening platform — the requirement is that the review follows Cochrane Handbook methodology, which any of these three tools can support.
Can I switch tools partway through a review?
+
Technically yes, via RIS/CSV export and re-import, but switching mid-screening risks losing in-progress conflict-resolution state and re-triggering deduplication — most teams pick one tool before screening starts specifically to avoid this.
Do any of these tools perform the meta-analysis itself?
+
No. All three manage screening and (for Covidence and DistillerSR) extraction, but the statistical synthesis step happens in dedicated meta-analysis software after data is exported.
Going deeper
